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ABSTRACT
Emerging hepatic models for the study of drug-induced toxicity include pluripotent stem cell-derived hepatocyte-like cells
(HLCs) and complex hepatocyte-non-parenchymal cellular coculture to mimic the complex multicellular interactions that
recapitulate the niche environment in the human liver. However, a specific marker of hepatocyte perturbation, required to
discriminate hepatocyte damage from non-specific cellular toxicity contributed by non-hepatocyte cell types or immature
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differentiated cells is currently lacking, as the cytotoxicity assays routinely used in in vitro toxicology research depend on
intracellular molecules which are ubiquitously present in all eukaryotic cell types. In this study, we demonstrate that
microRNA-122 (miR-122) detection in cell culture media can be used as a hepatocyte-enriched in vitro marker of drug-
induced toxicity in homogeneous cultures of hepatic cells, and a cell-specific marker of toxicity of hepatic cells in
heterogeneous cultures such as HLCs generated from various differentiation protocols and pluripotent stem cell lines,
where conventional cytotoxicity assays using generic cellular markers may not be appropriate. We show that the sensitivity
of the miR-122 cytotoxicity assay is similar to conventional assays that measure lactate dehydrogenase activity and
intracellular adenosine triphosphate when applied in hepatic models with high levels of intracellular miR-122, and can be
multiplexed with other assays. MiR-122 as a biomarker also has the potential to bridge results in in vitro experiments to
in vivo animal models and human samples using the same assay, and to link findings from clinical studies in determining
the relevance of in vitro models being developed for the study of drug-induced liver injury.
Key words: hepatocytes; drug-induced liver injury; microRNA; in vitro model; cytotoxicity; cell-specific biomarker; bridging
biomarker
Despite the development of various hepatic models for use in
screening for adverse effects of new drugs and to aid mechanis-
tic understanding of hepatotoxicity, drug-induced liver injury
(DILI) in humans remains a significant cause of patient morbid-
ity and mortality, and confers a major burden to the pharma-
ceutical industry and the regulatory authorities (Davies et al.,
2010; Olsen and Whalen, 2009). This is partly due to the major
limitations of currently available hepatic models in recapitulat-
ing in vivo functional and metabolic capabilities of the human
hepatocyte, most notably the expression of drug metabolizing
proteins such as cytochrome-P450 (CYP) enzymes, and drug
transporters which are important for a mechanistic under-
standing of drug-induced toxicity (Godoy et al., 2013). The most
metabolically active in vitro hepatic model is freshly isolated
human primary hepatocytes, although a myriad of issues limit
their application in the in vitro study of drug-induced toxicity
and safety screening (Kia et al., 2013). Human primary hepato-
cytes are not readily available, they are expensive, exhibit large
donor variations, and rapidly lose their functional phenotype
over time in in vitro culture, leading to reduced expression of the
majority of CYP enzymes (Godoy et al., 2013; Rodriguez-Antona
et al., 2002; Rowe et al., 2010).
A potential new hepatic model is the use of human pluripo-
tent stem cells to generate hepatocytes in vitro (Baxter et al.,
2010; Bone et al., 2011; Brolen et al., 2010). Directed differentiation
of human pluripotent stem cells into hepatocytes, typically
called hepatocyte-like cells (HLCs), with a mature functional
phenotype, could in theory provide a readily available source of
metabolically competent cells for use in drug screening
(Greenhough et al., 2010; Yildirimman et al., 2011). However, the
differentiation efficiency of HLCs from human pluripotent stem
cells can be variable, which is believed to be mainly due to
differences of the differentiation protocols being employed and
the propensity of the selected pluripotent stem cell line to
differentiate toward a hepatic lineage (Baxter et al., 2010; Bock
et al., 2011). The differentiation efficiency of HLCs from a starting
culture of undifferentiated pluripotent stem cells can range
from 9% to 90%, as determined by the percentage of cells in the
culture that express the hepatocyte protein marker albumin
(Hay et al., 2008; Rashid et al., 2010; Shiraki et al., 2008). Therefore,
for the application of HLCs as an in vitro model for drug screen-
ing and toxicology, this heterogeneity of maturity needs to be
accounted for.
Another approach taken to develop a relevant and
functional hepatic model includes efforts to better emulate the
in vivo liver tissue environment that mimics complex
multicellular and cell–matrix interactions. Examples include
the coculture of primary hepatocytes with non-parenchymal
cells such as hepatic sinusoidal endothelial cells and fibroblasts,
in either conventional 2-dimensional (2D) platforms or as 3-
dimensional (3D) spheroids (Bader et al., 1996; Bhatia et al., 1999).
More recently, a complex 3D quasi-liver “bud” was also success-
fully engineered from a coculture of human pluripotent stem
cell-derived HLCs with non-hepatocyte cell lines, and this
showed promising functional improvement of the HLCs
compared with conventional 2D culture (Takebe et al., 2013).
However, for the application of HLC cultures with hetero-
geneous maturity and complex hepatic coculture models in
the study of drug-induced toxicity, a hepatocyte-specific
marker of hepatocyte perturbation is needed to discriminate
non-specific cellular toxicity contributed by non-hepatocyte
cell types present within the model. This is currently lacking
as the cytotoxicity assays routinely used in in vitro toxicology
research depend on intracellular molecules which are ubiqui-
tously present in all eukaryotic cell types. Parameters
commonly used in cytotoxicity assays include the release of
the stable cytoplasmic molecule lactate dehydrogenase (LDH)
from necrotic cells, or change in the metabolic activity of via-
ble cells, by either relative quantification of intracellular
adenosine triphosphate (ATP), or reduction of substrates such
as tetrazolium salts by cellular oxidoreductase enzymes using
the MTT or MTS colorimetric assays (Lappalainen et al., 1994;
Mosmann, 1983; Slater, 2001). These intracellular molecules
and enzymes that are used in these assays are not cell-spe-
cific, and therefore the parameters described above to mea-
sure toxicity and cell viability can only be applied accurately
in models incorporating homogeneous cultures. Therefore, in
the emerging models of DILI which take the field beyond
assaying simple single hepatocytes or HLCs, current toxicolog-
ical endpoints largely reflect the global toxicity of the different
cell types in the culture, and are not able to specifically
measure only the perturbation of the hepatocytes or HLCs.
In this work, we explore the concept of using microRNA-122
(miR-122) as a potential hepatocyte-enriched marker of toxicity.
MicroRNAs (miRNAs) are highly conserved small non-coding
RNAs responsible for translational regulation of messenger
RNAs (Chen and Rajewsky, 2007; Lagos-Quintana et al., 2002).
Some miR species demonstrate high tissue enrichment, with
miR-122 shown to be highly enriched and abundant in adult
and foetal liver, constituting more than 70% of the total liver
miR content (Chang et al., 2004; Lagos-Quintana et al., 2002; Liu
et al., 2009; Sempere et al., 2004). miR-122 is involved in hepatic
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differentiation via a feedback loop with the liver-enriched
transcription factor network (Laudadio et al., 2012), and is also
highly upregulated in human embryonic stem cell (hESC)-
derived hepatocytes compared with undifferentiated stem cells
and early endodermal lineage cells (Kim et al., 2011). For these
reasons, several studies have evaluated miR-122 in the plasma
as a circulating hepatocyte-specific biomarker of various liver
injuries, including DILI in rodents and humans caused by drugs
such as acetaminophen and heparin (Antoine et al., 2013; Harrill
et al., 2012; Starkey Lewis et al., 2011; Wang et al., 2009).
Therefore, miR-122 could potentially be used as a bridging
biomarker to translate findings from in vitro experiments to
in vivo experiments and the clinical setting. However, to date,
the utility of miR-122 as an in vitro hepatocyte-enriched marker
of drug-induced toxicity has not been explored.
Therefore, using the prototypical hepatotoxicants acetamin-
ophen and diclofenac, we investigated the potential application
of miR-122 as a hepatocyte-enriched biomarker of drug-induced
toxicity in human primary hepatocytes and HLCs—hepatic
models with high levels of intracellular miR-122, and assessed
the sensitivity of the miR-122 toxicity assay in comparison with
conventional cytotoxicity assays in detecting drug-induced
hepatocyte perturbation.
MATERIALS ANDMETHODS
Human Subjects and Tissue
Human liver resections from surgical waste tissue were obtained
from adult patients (females [n¼ 2], males [n¼ 4]; mean age: 68
[54–76]) undergoing liver resections for hepatocellular carcinoma
(n¼ 4) or colorectal cancer metastases (n¼ 2), with full informed
consent and ethical approval from the relevant authorities
(National Research Ethics Service REC reference: 11/NW/0327).
Human Primary Hepatocyte Isolation and Culture
Human primary hepatocytes were isolated using a previously
described method with minor modifications (LeCluyse et al.,
2005). Briefly, liver resections were received as surgical waste
tissue immediately post-resection (Aintree University Hospital,
Liverpool, UK) and transferred on ice in HEPES buffer (10mM
HEPES, 136mM NaCl, 5mM KCl, 0.5% [wt/vol] glucose, pH 7.6) to
the laboratory. The liver resection specimens were then
perfused with HEPES-buffered saline (HBS) followed by digestion
with collagenase A (Roche) or collagenase IV (Sigma-Aldrich) in
HBS containing calcium. The suspension containing isolated
hepatocytes was then filtered through a nylon gauze and puri-
fied by centrifugation twice at 80 g for 5 min at 4C, before the
pellet was resuspended in Williams E medium (Sigma-Aldrich).
Following this, cell viability was determined using the trypan
blue exclusion method and the isolated hepatocytes were
deemed suitable for use in this study only if the viability is more
than or equal to 80%. The mean viability of the donor hepato-
cytes used in this study was 91(84–96)%.
The hepatocytes were then seeded onto collagen-I-
coated 24-well plates (BD Beckinson) at 2.5  105 cells/cm2 and
cultured in Williams E medium supplemented with 1% (vol/vol)
insulin-transferrin-selenium (from 100 stock solution, Life
Technologies), 2mM L-glutamine (Sigma-Aldrich), 107 M
dexamethasone (Sigma-Aldrich), and 1% (vol/vol) penicillin-
streptomycin (Sigma-Aldrich) at 5% CO2 and 37C. After 3 h,
non-attached cells were washed away and overlaid with fresh
ice-cold medium containing 0.25 mg/ml of Matrigel (BD
Beckinson). The media was replaced the next day at the start of
the experiments.
Human Cancer Cell Line Culture
The human hepatoma cell line (HepG2) and the pancreatic
cancer cell line (Suit-2) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 2mM L-glutamine
(Sigma-Aldrich), 10% (vol/vol) fetal bovine serum (FBS; Life
Technologies) and 1% (vol/vol) penicillin-streptomycin (Sigma-
Aldrich) at 5% CO2 and 37C.
Human Pluripotent Stem Cell Culture
The hESC line HUES7 was maintained on mitotically inacti-
vated murine embryonic fibroblasts (MEFs) as previously
reported (Baxter et al., 2009), in KnockOut DMEM (KO-DMEM;
Life Technologies) supplemented with 20% (vol/vol) KnockOut
Serum Replacement (KOSR; Life Technologies), 0.1mM non-
essential amino acids (NEAAs), 2mM L-glutamine (Life
Technologies), 1% (vol/vol) penicillin-streptomycin (Life
Technologies), 1% (vol/vol) insulin-transferrin-selenium (from
100 stock, ITS; Life Technologies), 0.1mM beta-mercaptoetha-
nol (Life Technologies), and 4 ng/ml fibroblast growth factor 2
(FGF2; PeproTech).
The hESC line Shef-3 was maintained on embryonic stem
cell-qualified Matrigel (BD Beckinson)-coated plates as
previously reported (Bone et al., 2011), in mTeSR1 (STEMCELL
Technologies).
Cell suspensions of human-induced pluripotent stem cells,
ChiPSC-18 (DEF-hiPSC, Cellartis by Takara Bio Europe AB), were
plated at a density of 70 000 cells/cm2 onto a proprietary matrix
as per protocol, and maintained using a proprietary feeder-free
and defined culture system, DEF-CS 500 (Cellartis by Takara Bio
Europe AB). ChiPSC-18 was generated using polycistronic retro-
virus technology based on the transduction of the transcription
factors Oct3/4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007).
Differentiation of Human Pluripotent Stem Cells into HLCs
The differentiation of HUES7 hESCs toward definitive endoderm
was commenced 3–4 days post-passage onto fresh MEFs in
Roswell Park Memorial Institute (RPMI) media (Sigma-Aldrich)
supplemented with 0.5% (vol/vol) FBS (Life Technologies),
100 ng/ml activin A (AA, PeproTech), and 25 ng/ml Wnt-3a (R&D
Systems) for 48 h, followed by 0.5% (vol/vol) FBS (Life
Technologies) and 100 ng/ml AA (PeproTech) without Wnt-3a
for a further 48 h. Hepatic specification was then carried out for
6 days in Hepatocyte Culture Medium (HCM; Lonza) supple-
mented with 20 ng/ml bone morphogenetic protein 2 (R&D
Systems) and 30 ng/ml FGF2 (PeproTech). For the hepatocyte
maturation stage, the HLCs were cultured in HCM supple-
mented with 20 ng/ml hepatocyte growth factor (HGF,
PeproTech) for 5 days followed by HCM supplemented with
10 ng/ml oncostatin M (R&D Systems) and 107 M dexametha-
sone (Sigma-Aldrich) for a further 15 days.
The differentiation of Shef-3 hESCs toward HLCs was
performed using a 3-stage differentiation protocol. Briefly, to
induce differentiation to definitive endoderm (DE), Shef-3 hESCs
were cultured in RPMI media (Life Technologies) containing
100 ng/ml AA (PeproTech) and 2 lM 1 m for 24 h, followed by
100 ng/ml AA and 0.2% (vol/vol) HyClone FBS (Fisher Scientific)
for 48 h. DE cells were then passaged as single cells with
Accutase (STEMCELL Technologies) onto Matrigel (BD
Beckinson)-coated 96-well plates at a density of 18 000 cells/
well. Hepatic specification was carried out for 7 days in KO-
DMEM supplemented with L-glutamine (Life Technologies), 0.5%
(vol/vol) penicillin-streptomycin (Life Technologies), 1mM
NEAA (Life Technologies), 2% (vol/vol) KnockOut Serum
Replacement (Life Technologies), 10 ng/ml HGF (PeproTech), and
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10 ng/ml fibroblast growth factor 4 (FGF4; PeproTech). To allow
for maturation, HLCs were cultured for 14 days in Williams E
medium supplemented with L-glutamine (Life Technologies),
0.5% (vol/vol) penicillin-streptomycin, 1% (vol/vol) ITS (from
100 stock, Life Technologies), 10 ng/ml oncostatin M
(PeproTech), 10 ng/ml HGF (PeproTech), 10 ng/ml FGF4
(PeproTech), 10 ng/ml epidermal growth factor (PeproTech), and
107 M dexamethasone (Sigma-Aldrich). During hepatic induc-
tion and maturation, medium was replenished every other day.
HLCs generated from ChiPSC-18 were received on Day 23 of
differentiation in plated 96-well plate formats (Enhanced
hiPS-HEP, Cellartis by Takara Bio Europe AB), and were main-
tained with proprietary media, HEP-104-SUP (Cellartis by Takara
Bio Europe AB).
Cytotoxicity Assays
Human primary hepatocytes, HLCs, and undifferentiated
human pluripotent stem cells were incubated for up to 24 h
with acetaminophen (0–30mM, Sigma-Aldrich) and diclofenac
(0–1mM, Sigma-Aldrich), which were dissolved and diluted to
the final test concentrations in the appropriate culture media.
The range of concentrations used in the cytotoxicity assays was
chosen to incorporate the concentration of 30 times the
reported efficacious concentration (Cmax) for each compound
in humans, which was suggested to be the optimal drug
concentration for in vitro prediction of human toxicity (O’Brien
et al., 2006).
The human primary hepatocytes and the hiPSCs (ChiPSC-18)
were treated with the test compounds 24 h after seeding, while
for the HLCs generated from ChiPSC-18, cytotoxicity assays
were started on Day 31 of differentiation.
LDH activity assay. For the human primary hepatocyte samples,
both the cellular lysates and media at the end of the experi-
ments were collected and assayed separately for LDH using the
Cytotoxicity Detection Kit (Roche). Briefly, the media were first
collected and the cells lysed in medium containing 2% (vol/vol)
Triton X-100 (Sigma-Aldrich). Both the media and cellular lysate
were then stored in 80C immediately. The level of LDH activ-
ity (a surrogate for the quantity of LDH molecules) in each sam-
ple was determined separately as per the manufacturer’s
instructions and the percentage of LDH activity in the media
was expressed as a percentage of the combined total intracellu-
lar and extracellular LDH activity in the well.
Intracellular ATP assay. The quantification of intracellular ATP in
HLCs and undifferentiated human pluripotent stem cells was
performed using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega). Following dosing of the cells with acetamino-
phen and diclofenac for 24 h, the media was collected first for
miR-122 analysis and the remaining adherent cells used for ATP
measurement. Briefly, 50 ll of Dulbecco’s phosphate-buffered
saline (DPBS) (Life Technologies) was added to each well fol-
lowed by 50 ll of CellTiter-Glo reagent which was prepared
according to the manufacturer’s protocol. The contents were
mixed in a plate shaker for 2 min to induce cell lysis and then
incubated for 10 min at room temperature. The cellular lysate
was then transferred to an opaque 96-well plate and the
luminescent signal measured using a Varioskan Flash spectral
scanning multimode reader (Thermo Scientific).
Total RNA Extraction
The purification of total RNA containing the miR fraction from
media or lysate samples was performed using the miRNeasy
mini kit (Qiagen), as per the manufacturer’s instructions, with
some modifications. Briefly, a typical 40 ll of media or lysate
diluted in RNAse-free water up to a total volume of 200 ll was
used for RNA purification in each experiment. Following
addition of 700 ll of QIAzol (Qiagen) to the diluted media or
lysate, and incubation at room temperature for 10 min, 5 ll of a
5 fM solution of cel-lin-4 (Integrated DNA Technologies) was
added as a spiked-in exogenous non-human miR to monitor for
the efficiency of the miR extraction process by evaluation of the
amount of recovered cel-lin-4 in each sample. 140 ll of chloro-
form was then added and the rest of the protocol was as per the
manufacturer’s instruction. The total RNA containing the miR
fraction was eluted with RNase-free water and quantification
performed using the NanoDrop spectrophotometer (Thermo
Scientific). The fully automated platform QIAcube (Qiagen) was
used in the extraction of total RNA containing miRs in the HLC
media samples.
Real-Time Quantitative RT-PCR (qRT-PCR) Analysis of miR-122
MiR-122 levels in each sample were determined using the
TaqMan gene expression assay (Applied Biosystems) according
to the manufacturer’s protocol. Briefly, a reverse transcription
(RT) cocktail mixture containing specific stem-loop RT primers
for each target miR species (Applied Biosystems) was prepared
as instructed and added to 5 ll of the total RNA elute for com-
plementary DNA (cDNA) synthesis in a total volume of 15 ll.
1.33 ll of cDNA was then mixed with a PCR mixture containing
specific stem-loop PCR primers in a total volume of 20 ll. Real-
time PCR was then performed in duplicates using the ABI Prism
7000 or ViiA 7 instruments (Applied Biosystems) using a 2-step
thermal cycling protocol of 95C for 10 min followed by 40 cycles
of 95C (15 s) and 60C (60 s). Ct values were determined using
the fluorescent signal produced from the TaqMan probes. The
number of copies of miR-122 in each PCR reaction was quanti-
fied using the absolute quantification method with a standard
curve of cel-lin-4 cDNA used as a surrogate for miR-122 cDNA,
due to its similar nucleotide length and to avoid contamination
of PCR reactions with synthetic miR-122. The total number of
copies of miR-122 in each sample was then extrapolated from
this figure. The amplification efficiency of cel-lin-4 cDNA was
confirmed in independent experiments to be comparable to
that of miR-122 cDNA, with similar standard curves
constructed. For the human primary hepatocyte samples, both
the total copies of miR-122 in the cellular and media compo-
nents were determined separately, and the percentage of
miR-122 in the media was expressed as a percentage of the
combined total of intracellular and extracellular miR-122 copies
in the well, analogous to the LDH cytotoxicity assay.
Immunocytochemistry
Immunocytochemistry was performed on undifferentiated
ChiPSC-18, 1 day after passage, and at Day 28 of differentiation
for ChiPSC-18-derived-HLCs, as previously described (Ulvestad
et al., 2013). Briefly, cells were fixed in 4% (wt/vol) formaldehyde
(Histolab) for 20 min followed by repeated washes in DPBS
(Life Technologies). Fixed cells were incubated in a blocking buf-
fer (DPBS, Life technologies) containing 5% (wt/vol) skim
milk (Sigma-Aldrich) and 0.2% (vol/vol) Triton X-100 (Sigma-
Aldrich) for 30 min followed by overnight incubation with the
relevant primary antibody at 4C. After 3 washes in DPBS
(Life Technologies), the fixed cells were incubated with the
appropriate secondary antibody for 2 h in the dark, at room
temperature, before the cells were washed 3 times again with
DPBS containing 0.5 lg/ml 40,6-diamidino-2-phenylindole (DAPI,
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Sigma–Aldrich) for nuclear staining, and mounted in
Fluorescence Mounting Medium (Dako). Primary and secondary
antibodies were diluted in an incubation solution consisting of
1% (vol/vol) bovine serum albumin (Sigma-Aldrich) and 0.2%
(vol/vol) TritonX-100 (Sigma-Aldrich). The following primary
and secondary antibodies were used: mouse anti-Oct3/4 (1:200,
sc-5279, SantaCruz Biotechnology), rabbit anti-HNF4a (1:400,
sc-8987, Santa Cruz Biotechnology), rabbit anti-a-1-antitrypsin
(1:200, a0012, Dako), mouse anti-cytokeratin-18 (1:100, M7010,
Dako), Alexa Fluor 488 goat anti-mouse IgG (1:1000, A-11029,
Life Technologies), Alexa Fluor 488 donkey anti-rabbit IgG
(1:1000, A-21206, Life Technologies), and Alexa Fluor 594 goat
anti-mouse IgG (1:1000, A-11032, Life Technologies). Stainings
were analyzed using a fluorescence microscope (Eclipse TE2000-
U, Nikon), a digital camera (DXM1200C, Nikon) and correspond-
ing software (Act-1C software for DXM1200C camera, Nikon).
Technical control stainings without primary antibodies were
performed for all secondary antibodies, and were all negative
(data not shown).
Statistical analysis
For comparison of the intracellular miR-122 level between mod-
els, the mean and the standard error of the mean of each model
were determined. For comparisons between each model with
human primary hepatocytes, the Mann-Whitney non-paramet-
ric test was used, whereas the Dunn’s multiple comparison test
was used for comparison of more than 2 models. For the cyto-
toxicity assays, the unpaired t-test was used for pairwise com-
parisons, while correlation analyses were performed using the
Pearson correlation test. For all tests, P< 0.05 was considered
significant. Statistical analyses were performed using GraphPad
Prism 6 (GraphPad Software, La Jolla, California).
RESULTS
Intracellular miR-122 Levels Reflect the Physiological Relevance of
Human Hepatic Models
Freshly isolated human primary hepatocytes are currently
considered to be the most physiologically relevant single cell
in vitro hepatic model, particularly due to their functional
recapitulation of the in vivo metabolic processes such as phase I
and II enzyme activities, glucose metabolism, and ammonia
detoxification (Godoy et al., 2013; Kia et al., 2013). Therefore, to
investigate the relevance of miR-122 as a potential biomarker in
in vitro hepatic models, we first performed quantification of the
intracellular level of miR-122 among the commonly used hep-
atic models of HepG2 (a hepatocellular cancer cell line) and
human pluripotent stem cell-derived HLCs in direct comparison
to freshly isolated and plated human primary hepatocytes from
adult donors.
We found that the mean intracellular miR-122 level
normalized to the amount of total RNA used for qRT-PCR is the
highest in human primary hepatocytes with a 9- to 41-fold
lower expression in hPSC-derived HLCs, and 2500-fold lower in
HepG2 (Fig. 1). Human primary hepatocytes also expressed sig-
nificantly more miR-122 compared with undifferentiated hPSCs
(3900- to 78 000-fold lower) and the pancreatic cancer cell line
Suit2 (17 000-fold lower), which was included as part of the
comparison as a negative control for non-hepatic cells of the
endodermal lineage.
Overall, the results in Figure 1 confirm that miR-122 is highly
enriched in human primary hepatocytes and provide a quanti-
tative comparison of intracellular miR-122 among the most
relevant human hepatic in vitro models currently used.
MiR-122 Expression Increases during Directed Differentiation of
hESCs and hiPSCs Toward HLCs
In HLCs differentiated from their respective hESC lines, the
mean fold increase of miR-122 from basal levels in their
originating undifferentiated hESC lines was similar (420- and
430-fold change, respectively), whereas in the HLCs differenti-
ated from the hiPSC line (ChiPSC-18), the mean increase in
miR-122 level was higher at 3500-fold (Fig. 1). However, there
was no significant difference between the mean intracellular
miR-122 levels among the HLCs derived from the 2 hESC lines
and ChiPSC-18, or between the low levels of mean intracellular
miR-122 detected in the undifferentiated pluripotent stem cell
lines.
The Relative Level of miR-122 Detected in the Media Correlates with
the Extracellular Release of LDH in Drug-Induced Toxicity of Human
Primary Hepatocytes
To explore the potential of miR-122 as an in vitro marker of
drug-induced cellular perturbation, we first compared its
performance against the conventional marker of cellular
necrosis, LDH, using human primary hepatocytes. We chose to
validate miR-122 against LDH, as the levels of LDH and miR-122
can be readily measured in both the cellular lysate and media
component, which allows for direct comparison of the sensitiv-
ity of both markers in detecting drug-induced toxicity.
Dose-response experiments using human primary hepato-
cytes incubated with the known hepatotoxicants acetamino-
phen and diclofenac for 24 h (Figs. 2A and 2B) were performed.
The LDH activity in the media and cellular fraction of each well
were separately measured to calculate the relative percentage
of total LDH activity in the media. In parallel experiments, using
the same donor-batch of human primary hepatocytes, we also
quantified the number of copies of miR-122 in the media and
cellular fraction in response to acetaminophen and diclofenac,
and calculated the relative percentage of total miR-122 in the
media (Figs. 2A and 2B). We found that the level of miR-122
increased in the media with increasing concentrations of acet-
aminophen and diclofenac, which paralleled the extracellular
release of intracellular LDH. Significant levels of both molecules
were detected in the media at the maximal concentrations of
acetaminophen and diclofenac used in this study (Figs. 2A and
2B). By plotting the paired values of each biomarker obtained
from the experiments using various concentrations of acetami-
nophen and diclofenac in a scatter graph, we confirmed that
there was a high positive correlation between the levels of LDH
and miR-122 in the media (Pearson’s correlation coefficient,
r¼ 0.993, P< 0.0001, 95% CI 0.974–0.998) (Fig. 2C). This suggests
that using the model of human primary hepatocytes, miR-122 is
equivalent to LDH when used as an in vitro biomarker of
drug-induced toxicity.
We also performed a time-course experiment on the hepato-
cytes treated with diclofenac over 24 h and observed compara-
ble trends in both biomarkers in the media with a concentration
of 1mM (Figs. 3A and 3B). Increased levels of both biomarkers
were detected in the media after 2 h, although significant levels
were only detected at 24 h using either biomarker (Figs. 3A and
3B). This suggests miR-122 is as sensitive as LDH when used as
a toxicity marker for human primary hepatocytes but the time-
course experiments using diclofenac as the test compound did
not point toward the possibility of miR-122 providing an earlier
signal of hepatocyte perturbation compared with LDH.
We also observed that the miR-122 level in the media has a
wider dynamic range compared with LDH. In both sets of
dose-response experiments, the untreated human primary
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hepatocytes showed a baseline mean percentage of total LDH in
the media at 24 h of 6.4% and 6.9%, respectively, compared with
a baseline mean percentage of total miR-122 of 1.8% and 1.4%
(Figs. 2A and 2B). When a toxic concentration of 30mM acetami-
nophen was used, the mean increase over baseline of LDH in
the media was 6.8-fold compared with a higher mean increase
of 25-fold for miR-122 (Fig. 2A). Similarly, human primary hepa-
tocytes treated with 1mM diclofenac showed a mean increase
over baseline of LDH in the media of only 8.9-fold compared
with a higher mean increase of 53-fold for miR-122 (Fig. 2B).
We then sought to simplify the miR-122 assay further and
observed that the estimation of the total copies of miR-122 in
the media alone is sufficiently predictive of the relative percent-
age of total miR-122 in the media. It has a wide dynamic range
and the denominator of the total number of copies of miR-122
in both the cellular lysates and the media component remained
fairly constant throughout the various validation experiments
(Supplementary Figs. 1 and 2). Using the experimental values
obtained from the dose-response experiments of hepatocytes
treated with various concentrations of acetaminophen and
diclofenac, we found a high positive correlation between the
mean percentage of total miR-122 and the mean number of
copies of miR-122 in the media (Pearson’s correlation coeffi-
cient, r¼ 0.967, P< 0.0001, 95% CI 0.882–0.991) (Supplementary
Fig. 3A). There was also a similarly high positive correlation
between the mean percentage of total LDH activity and the
mean number of copies of miR-122 in the media (Pearson’s cor-
relation coefficient, r¼ 0.945, P< 0.0001, 95% CI 0.810–0.985)
(Supplementary Fig. 3B). Therefore, by absolute quantification
of the number of copies of miR-122 in the media alone, the miR-
122 assay as a biomarker of toxicity is made simpler without the
need to measure the miR-122 level in the cell lysate component.
Drug-induced perturbation of the hepatic models can be
evaluated using only the media component by relative compari-
son with the baseline levels of miR-122 in the media.
The Level of miR-122 in the Media Reflects Hepatocyte-Specific
Drug-Induced Toxicity in hiPSC-Derived HLCs
We then explored the use of miR-122 in complex human hepatic
models which may not be homogeneous such as cultures of
HLCs, where the differentiation efficiency can be variable and
not 100% predictable (Baxter et al., 2010; Kia et al., 2013).
Conventional cellular markers of toxicity such as LDH and ATP,
and others used in multiparametric high content screening
platforms, do not discriminate between toxicity affecting hepa-
tocyte and non-hepatocyte cells present in the culture (Rausch,
2006). We hypothesized that the hepatocyte-enriched expres-
sion of miR-122 could be used to detect selectively drug-induced
perturbation of the HLCs in non-homogeneous cell cultures.
The use of miR-122 as an in vitro biomarker in HLCs was
explored using ChiPSC-18-derived HLCs, which were
characterized with immunocytochemical analysis and con-
firmed to express the hepatic markers hepatocyte nuclear factor
4 alpha (HNF4a), alpha-1-antitrypsin and cytokeratin-18
(Figs. 4A–D), and did not express the pluripotency marker Oct3/4
(data not shown). About 90% of the HLCs have a typical hepatic
morphology and HNF4a immuno-positive nuclei. The HLC cul-
tures were incubated with the same hepatotoxicants (acetami-
nophen and diclofenac), and compared against the sensitivity
of intracellular ATP quantification by multiplexing both assays
in the same experiments. We chose to use the intracellular ATP
assay instead of the LDH activity assay to compare against the
miR-122 assay for the cytotoxicity experiments utilizing HLCs,
as the much smaller volume of media available for each culture
of HLCs (100 ml total volume per well in a 96-well plate format)
did not allow for sufficient material for both extraction of miRs
FIG. 1. Quantitative comparison of intracellular miR-122 between human hepatic models. Data are presented as the mean total number of copies of intracellular miR-
122 per mg of total RNA6SEM for human primary hepatocytes, hPH (n¼6 different donors), HLCs differentiated from HUES7 and Shef-3 hESC lines (n¼3 separate differ-
entiation experiments each), HLCs differentiated from ChiPSC-18 hiPSC line (n¼3 separate differentiation experiments), HepG2 (n¼3 biological replicates from one
experiment), Suit2 (n¼3 biological replicates from one experiment) and undifferentiated human pluripotent stem cell (hPSC) lines (n¼ 3 independent experiments
each). The Mann-Whitney non-parametric test was used to compare each model against human primary hepatocytes for statistical significance, whereas the Dunn’s
multiple comparison test was used when performing comparisons between HLCs and between the undifferentiated pluripotent stem cell lines. *P<0.05, **P<0.01, ns
denotes non-significance.
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and quantification of the LDH activity in the media. However,
the intracellular ATP assay has been separately validated by our
group for assessment of drug-induced hepatocyte perturbation
in freshly isolated adult human primary hepatocytes, using a
similar dose range of acetaminophen and diclofenac (n¼ 8 and
6 different donors, respectively). In those experiments, the end-
point of change in intracellular ATP level was confirmed to
correlate significantly with the percentage of total LDH activity
in the media, percentage of total miR-122 in the media and the
number of copies of miR-122 per million cells in the media (data
to be published elsewhere).
In parallel experiments, we also used the undifferentiated
hiPSCs (ChiPSC-18) (Figs. 4E and 4F) from which the HLCs were
derived from, as a surrogate for poorly differentiated cells
present in HLC cultures that do not possess a hepatic phenotype
and express a very low level of intracellular miR-122 relative to
hepatic cells, to examine the hepatic specificity of miR-122 as
an in vitro marker of toxicity. Each batch of HLCs or hiPSCs were
treated with acetaminophen or diclofenac over 24 h, and the
lysate was used for the ATP assay, while the media from the
same well was collected in order to estimate the number of
copies of miR-122 (Figs. 5A–D). Using the ATP assay, perturba-
tion of the HLCs was detected, with a mean reduction of ATP of
35% and 33%, respectively, at 24 h, when the cells were treated
with the highest concentrations of acetaminophen and diclofe-
nac (Figs. 5A and 5B). However, the non-hepatocyte model of
hiPSCs displayed a greater reduction in ATP levels, with lower
concentrations of acetaminophen (56% with 10mM and 99%
FIG. 2. Dose-response of human primary hepatocytes after treatment with acet-
aminophen and diclofenac. Percentage of total LDH and miR-122 in the media of
human primary hepatocytes at 24 h post-treatment with (A) acetaminophen and
(B) diclofenac. Data are presented as the mean6SEM from 3 independent experi-
ments using different donors of human primary hepatocytes. For each donor
batch of hepatocytes, parallel experiments were performed in duplicates to com-
pare the sensitivity of LDH and miR-122 as biomarkers. The unpaired t-test was
used to compare the statistical significance of the dose-response as measured by
the percentage of total marker in the media for each concentration of hepatotoxi-
cant against the respective untreated controls. *P<0.05, **P<0.01, †P<0.0001. (C)
Correlation of the percentage of total LDH in the media against the percentage of
total miR-122 in the media, using paired mean values for each condition obtained
from experimental results summarized in Figures 2A and 2B. r denotes Pearson’s
correlation coefficient, CI denotes the confidence interval of r.
FIG. 3. Hepatotoxicity of human primary hepatocytes treated with diclofenac up
to 24 h. Time-course experiment of human primary hepatocytes treated with
diclofenac up to 24 h as measured by (A) percentage of total LDH in the media
and (B) percentage of total miR-122 in the media. Data are presented as the
mean6SEM from 3 independent experiments using different donors of human
primary hepatocytes. For each donor batch of hepatocytes, parallel experiments
were performed in duplicates to compare the sensitivity of LDH and miR-122 as
biomarkers. The unpaired t test was used to compare the statistical significance
of the percentage of total marker in the media at each time-point compared
with untreated controls. *P< 0.05.
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with 30mM), confirming ATP as a generic and non-cell-type-
specific marker of cellular perturbation (Fig. 5A). In contrast, the
hiPSCs, when treated with diclofenac, displayed increased ATP
levels of up to 196% of baseline (Fig. 5B).
Using miR-122 as a marker for drug-induced toxicity in the
same experiments, a trend toward an increase in the number of
copies of miR-122 in the media of HLCs was noted with acetami-
nophen and diclofenac, with a mean 4-fold and 6-fold increase
from baseline, respectively, at the highest concentrations used
in these experiments (Figs. 5C and 5D). This suggested that
when the miR-122 assay was used as a toxicity assay for the
HLCs, its performance was as sensitive as the ATP assay. This
was confirmed by a correlation analysis using the paired values
of both assays from the experiments using HLCs treated with
acetaminophen and diclofenac at various concentrations
(Fig. 6A). By plotting the values in a scatter graph, a significant
negative correlation was found (Pearson’s correlation coeffi-
cient, r¼0.862, P< 0.001, 95% CI 0.961 to 0.571).
However, in contrast to the varying intracellular ATP pro-
file seen in the hiPSCs incubated with acetaminophen and
diclofenac (Figs. 5A and 5B), the miR-122 level in the media
did not display any increasing trend throughout the range
of concentrations of the hepatotoxicants (Figs. 5C and 5D).
Analysis utilizing the paired values of both biomarkers from
the experiments using hiPSCs described above, also showed
no correlation between the levels of miR-122 in the media
and the change in intracellular ATP levels in the hiPSCs
(Pearson’s correlation coefficient, r¼ 0.041, P¼ 0.901, 95% CI
0.546 to 0.601).
The total number of copies of miR-122 expressed by an
equivalent number of hiPSCs was also at least 78-fold less than
that expressed by the HLCs, and therefore the potential contrib-
utory effect of miR-122 from the non-hepatocyte cells in HLC
cultures toward the total number of copies of miR-122
measured in the media was negligible. More importantly, at the
toxic concentrations of acetaminophen and diclofenac, where a
reduction of intracellular ATP level and an increase in miR-122
in the media of treated HLCs was detected (Figs. 5A–D), the
corresponding miR-122 level in the media of hiPSCs treated
with the same concentrations remained unchanged. Thus, the
source of increased level of miR-122 in a heterogeneous
culture such as HLCs treated with toxic concentrations of
FIG. 4. Characterization of ChiPSC-18-derived hepatocyte-like cells (HLCs) and undifferentiated human induced pluripotent stem cells (ChiPSC-18). Phase contrast
pictures of ChiPSC-18-derived HLCs (A) and undifferentiated ChiPSC-18 (E). Immunocytochemical analysis of the expression of the hepatic markers HNF4a (B),
a-1-antitrypsin (C), and cytokeratin-18 (D) in combination with DAPI (nuclear stain) for ChiPSC-18-derived HLCs at day 28 of differentiation, and the expression of the
pluripotency marker Oct3/4 in undifferentiated ChiPSC-18 (F). Scale bar: 50 mm (A–F). Hepatocyte nuclear factor 4, HNFa; 40 ,6-diamidino-2-phenylindole, DAPI.
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hepatotoxicants was likely to be from hepatic cells with a high
level of intracellular miR-122—in this case well-differentiated
HLCs.
DISCUSSION
MicroRNA-122 has been shown to be a liver-enriched and -
abundant miR, which could be useful as a bridging biomarker of
drug-induced hepatotoxicity to translate findings from in vitro
experiments to in vivo experiments and the clinical setting.
However, quantitative evaluation of its abundance in
various in vitro hepatic models currently used for the study of
drug-induced hepatotoxicity in comparison to human primary
hepatocytes has not been considered. For this study, we first
confirmed that the in vitro hepatic models examined express
high levels of miR-122, in contrast to the non-hepatic models
(Fig. 1). The lower intracellular miR-122 levels in the various
models in comparison to freshly isolated human primary hep-
atocytes suggest that the quantity of intracellular miR-122
broadly reflects the models’ degree of hepatic phenotype.
Although HLCs differentiated in conventional 2D cultures have
not yet been reported to display a full complement of drug
metabolizing enzymes at comparable levels to human primary
hepatocytes (Kia et al., 2013; Sjogren et al., 2014; Ulvestad et al.,
2013), nevertheless HLCs derived from pluripotent stem cell
lines with normal genotypes would be expected to exhibit a
physiologically more relevant hepatic phenotype compared
with liver cancer cell lines. This has been confirmed in studies
directly comparing the drug metabolizing capacity of pluripo-
tent stem cell-derived HLCs and the hepatocellular cancer cell
lines, HepG2 and HuH7 (Brolen et al., 2010; Sjogren et al., 2014;
Soderdahl et al., 2007). Therefore, miR-122 can also be poten-
tially exploited as a biomarker of physiological relevance of
current and emerging in vitro hepatic models for mechanistic
studies of DILI, by correlating their intracellular level of miR-122
to the biochemical and functional phenotype. This work is
underway and will be reported elsewhere.
Figure 1 also supports a previous observation that the miR-
122 expression increases during directed differentiation of
hESCs toward HLCs (Kim et al., 2011). In that study, only a single
hESC line was used for HLC generation using a different protocol
to those used in this study. Hence, our study adds to that find-
ing as we used 2 different hESC lines, maintained in both feeder
and feeder-free culture conditions, and differentiated toward
HLCs using 2 disparate protocols. This study also demonstrates
for the first time that HLCs differentiated from hiPSCs exhibit a
similar trend of increase in miR-122 expression to hESC-derived
HLCs, although only one hiPSC line was examined in this study.
In homogeneous hepatic models, such as plated human pri-
mary hepatocytes or HLC cultures derived with high differentia-
tion efficiencies, we propose that the miR-122 cytotoxicity
assay, which has marked concordance with the conventional
assays utilizing generic markers (Figs. 2, 3, and 6), is a more rele-
vant cell-type-specific assay to examine drug-induced toxicity
of the hepatic cells. One major advantage of using miR-122 as
an in vitro biomarker is the potential to translate such in vitro
findings to in vivo animal models and human samples using the
same assay, as miR-122 in the plasma has been shown to be an
appropriate marker of acetaminophen-induced liver injury in a
mouse model and in humans (Antoine et al., 2013; Harrill et al.,
2012; Starkey Lewis et al., 2011; Wang et al., 2009). In other words,
miR-122 can be used to bridge results in in vitro experiments to
clinical findings, and conversely used to link findings from clini-
cal studies to inform on the relevance of in vitro models being
developed for the study of DILI, which the current conventional
in vitro markers such as LDH and ATP could not provide.
FIG. 5. Dose-response of hepatocyte-like cells (ChiPSC-18-derived HLCs) and undifferentiated human-induced pluripotent stem cells (ChiPSC-18) after treatment with
acetaminophen and diclofenac. (A, B) Intracellular ATP level (expressed as percentage of vehicle control) and (C, D) number of copies of miR-122 per million cells in the
media of hiPSC-derived HLCs and undifferentiated hiPSCs treated with acetaminophen and diclofenac for 24 h. Data are presented as the mean6SEM from 3 inde-
pendent experiments. For the HLCs, each independent experiment represented HLCs from separate differentiation experiments, whereas for the hiPSCs, each inde-
pendent experiment represented separate batches of hiPSCs plated on different days. The cytotoxicity assays were performed in at least two replicates on HLCs and
hiPSCs cultured in 96-well plates. The number of copies of miR-122 estimated in the media was normalized to the number of cells estimated to be present in the HLC
and hiPSC cultures to allow for a direct comparison of absolute quantities of miR-122 in the media. The density of HLCs present in a single well was estimated to be
about 1  105 cells/cm2 when the HLC culture was fixed and stained with the nuclear stain DAPI (data not shown). As the total cell culture surface per well was 0.32
cm2, a total number of 3.2 104 HLCs per well was obtained. For the hiPSCs, a total number of 2.2104 hiPSCs per well was obtained using the plating density of 7105
cells/cm2.
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Similarly, in models where heterogeneity of the hepatic
phenotype is present such as in HLC cultures with moderate or
variable differentiation efficiencies, the miR-122 cytotoxicity
assay may be essential as it allows for specific assessment of
the effect of hepatotoxicants on the hepatic cells and the ability
to discriminate from the “noise” of the surrounding non-hepa-
tocytes. For example, determining the relative intracellular ATP
levels between mature HLCs and poorly differentiated endoder-
mal progenitors or differentiated cells of other lineages in a
typical HLC culture would not be possible, as the ATP assay
readout reflects the composite of all the ATP content present
within a culture. Therefore, it is not possible to measure specifi-
cally the dose-response of mature HLCs toward hepatotoxicants
in a heterogeneous culture using the ATP assay or any other
assays utilizing biomarkers ubiquitously present in all cells,
such as LDH. This was borne out in our study where the
non-hepatocyte model of hiPSCs displayed higher levels of tox-
icity as measured by the reduction of intracellular ATP levels at
lower concentrations of acetaminophen, likely through non-
CYP-dependent mechanisms, confirming ATP as a generic and
non-cell-type-specific marker of cellular perturbation (Fig. 5A).
Conversely, the ATP levels in hiPSCs treated with diclofenac
increased up to 196% of baseline (Fig. 5B), though the reason for
this increase is unknown and the effect of diclofenac on human
pluripotent stem cells has not been reported in the literature.
The utility of the miR-122 cytotoxicity assay for the specific
assessment of the effect of hepatotoxicants on hepatic cells is
also potentially applicable in complex 2D or 3D hepatic models
of human hepatocytes cocultured with their non-parenchymal
counterparts, which are widely considered to be the ideal in vitro
hepatic models as they mimic the complex multicellular inter-
actions that recapitulate the niche environment in the human
liver (Godoy et al., 2013). Indeed, progress has been reported in
using human hepatocytes and pluripotent stem cell-derived
HLCs in cocultures with non-hepatocyte cells to produce in vitro
hepatic models with an improved functional phenotype (Bhatia
et al., 1999; Takebe et al., 2013). Although the coculture with non-
hepatocyte cells enhances the functional phenotype of the hep-
atic cells, their concomitant presence could conceivably compli-
cate the analysis of toxicity specifically targeting the
hepatocytes, using the currently available conventional cyto-
toxicity assays. Indeed, one reported approach in a coculture
FIG. 6. Correlation of intracellular ATP activity with miR-122 level in the media. Correlation between intracellular ATP activity (expressed as percentage of vehicle con-
trol) and number of copies of miR-122 per million cells in the media of (A) hiPSC-derived HLCs and (B) undifferentiated hiPSCs, treated with acetaminophen and diclofe-
nac over 24 h using paired mean values obtained from experimental results summarised in Figure 4. r denotes Pearson’s correlation coefficient, CI denotes the
confidence interval of r.
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model of rat primary hepatocytes and murine stromal support
cells to calculate the hepatocyte-only responses for non-hepa-
tocyte-specific endpoints such as intracellular ATP and gluta-
thione in response to drug-induced toxicity, was to perform
simultaneous assays on cultures of the stromal cells alone and
to subtract subsequent values from that obtained from the
cocultures (Ukairo et al., 2013). However, this approach does not
truly encompass the effect of the multicellular interaction
between the hepatocytes and the stromal cells in response to
events causing cellular perturbation, such as drug-induced tox-
icity. An ideal biomarker in these cocultures would be one
which is specifically and dynamically changed only in the hep-
atic cells, and can be measured directly in the cocultures. We
propose that miR-122 is one such hepatocyte-enriched marker
that can be applied in hepatic models that incorporate hepato-
cytes or HLCs that express high levels of miR-122.
Although we have shown the utility of miR-122 in the
human primary hepatocyte and HLC models, validation
experiments of its predicted utility in complex coculture hepatic
models still need to be conducted. Similarly, the utility of the
miR-122 assay could be considered in high content cellular
screening assays widely adopted by the pharmaceutical indus-
try, which currently look at organelle-specific toxicity or screen
for cellular perturbation events that are not hepatocyte specific
(Rausch, 2006). Therefore, in these screening assays changes in
endpoints will be detected as readily in non-hepatocyte cells as
in hepatocytes.
In a practical sense, as the miR-122 cytotoxicity assay
described here uses quantitative RT-PCR, only a small amount
of miR-122-containing media is required—we have extracted
adequate miR-122 for analysis using as little as 50 ll of media
from a total volume of 100 ll used to maintain 2.2  104 hiPSCs
in a 96-well format. This assay can also be multiplexed simulta-
neously with other cytotoxicity assays that require a portion of
the media and/or cellular lysate components. Furthermore, the
miR-122 assay also allows for repetitive sampling during
chronic dosing experiments, which may be a more relevant
approach to studying human DILI in in vitro hepatic models, and
will also enable sampling of hepatocyte damage in complex 3D
bioreactor cultures. A disadvantage of this assay compared with
other conventional cytotoxicity assays that mainly use plate
readers for endpoint readouts is that the quantification of
miR-122 in the media for each sample involves multiple
preprocessing steps of RNA extraction and RT. So far, the miR-
122 cytotoxicity assay has not been applied as high-throughput
readouts, but our workflow in using this assay benefits from the
availability of automated platforms of RNA extraction, an auto-
mated instrument for PCR setup and a PCR platform for
analyzing a 384-well PCR plate format.
Although the application of miR-122 for detecting drug-
induced toxicity is shown in this study, the basis for the
increase of miR-122 in the media during drug-induced toxicity
is still unclear. However, our finding of a high correlation
between the increases in LDH and miR-122 in the media of
human primary hepatocytes treated with hepatotoxicants
suggests that miR-122 may be passively released from necrotic
cells (Figs. 2 and 3), which is in keeping with the finding that
miR-122 predominantly is increased in the protein-rich fraction
rather than the exosome-rich fraction in the plasma/serum
samples of a mouse model of acetaminophen-induced liver
injury (Bala et al., 2012). It was postulated that as acetamino-
phen-induced liver injury is severe and rapid, miRs may be
released primarily through leakage from dying hepatocytes, as
opposed to release through exosomes in liver injuries which are
less severe and slower such as in alcoholic liver disease.
However, increased cellular-mediated release of miR-122 in
microparticles, exosomes, or protein complexes as a response
to toxic chemical exposure cannot be excluded (Salminen et al.,
2011). It is also unclear if drug-induced toxicity per se or individ-
ual drugs have any effect on the synthesis or degradation of
mature miR-122, although data shown in Supplementary
Figures 1 and 2 suggest that the hepatotoxicants examined in
this study at least, have no effect on the steady state level or the
total number of copies of miR-122 in the human primary hepa-
tocyte cultures. Defining the effects of other hepatotoxicants
that induce DILI through other mechanisms such as cholestasis
and steatosis on the dynamics of miR-122 release may help in
unravelling this uncertainty. Nevertheless, the data presented
here establish the potential of miR-122 as a useful in vitro
marker of drug-induced toxicity. Bridging in vitro and in vivo
studies can now be performed to further define the mecha-
nism(s) of miR-122 release, which will enhance the mechanism-
based utility of miR-122 both as a quantitative and qualitative
marker of liver injury.
In summary, this report demonstrates that miR-122 detec-
tion in cell culture media can be used as an in vitro marker of
drug-induced cytotoxicity in homogeneous cultures of hepatic
cells, and also can be applied as a hepatocyte-enriched marker
of toxicity in heterogeneous cultures of hepatic cells.
Furthermore, these results indicate the potential of miR-122 to
be used in hepatic models using coculture with non-hepatocyte
cells, where use of conventional cytotoxicity assays employing
generic cellular markers may not be appropriate. We show that
the sensitivity of the miR-122 cytotoxicity assay is similar to
conventional assays measuring LDH activity and intracellular
ATP levels in hepatic cultures, and that this can be multiplexed
with other assays. Future challenges include defining the mech-
anism(s) by which miR-122 is released into the media and
understanding the effect of drugs on miR-122 biogenesis and
stability.
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